CLVS Share Price

Open 71.93 Change Price %
High 72.57 1 Day -0.76 -1.06
Low 70.50 1 Week -0.68 -0.95
Close 71.20 1 Month -15.44 -17.82
Volume 937938 1 Year 53.10 293.37
52 Week High 99.45
52 Week Low 16.61
CLVS Important Levels
Resistance 2 73.12
Resistance 1 72.33
Pivot 71.42
Support 1 70.07
Support 2 69.28
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.13 -13.33%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
ARCI 1.45 137.70%
FALC 0.40 60.00%
AMCF 0.03 50.00%
LOCM 0.09 50.00%
OPXAW 0.10 42.86%
VRTA 4.50 38.46%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Clovis Oncology, Inc. (NASDAQ: CLVS)

CLVS Technical Analysis 1.5
As on 21st Aug 2017 CLVS Share Price closed @ 71.20 and we RECOMMEND Buy for LONG-TERM with Stoploss of 56.30 & Sell for SHORT-TERM with Stoploss of 80.80 we also expect STOCK to react on Following IMPORTANT LEVELS.
CLVS Target for August
1st Target up-side 93.62
2nd Target up-side 99.8
3rd Target up-side 105.98
1st Target down-side 76
2nd Target down-side 69.82
3rd Target down-side 63.64
CLVS Other Details
Segment EQ
Market Capital 588133504.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.clovisoncology.com
CLVS Address
CLVS
2525 28th Street
Suite 100
Boulder, CO 80301
United States
Phone: 303-625-5000
Fax: 303-245-0360
CLVS Latest News
Interactive Technical Analysis Chart Clovis Oncology, Inc. ( CLVS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Clovis Oncology, Inc.
CLVS Business Profile
Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.